The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

A recent congressional hearing on 340B is the latest iteration of a standoff between two pillars of the healthcare industry—hospitals and pharmaceutical manufacturers—both of which have powerful ...

This past September, a sub-agency of the Department of Health and Human Services (HHS) threatened to kick a pharmaceutical company out of Medicare because the company, in line with federal law, ...

The Department of Health and Human Services is scrapping the 340B Drug Pricing Program’s rebate model, according to a Thursday court filing. Hospitals are reacting with glee, as the rebate model would ...

More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...

The 340B Drug Pricing Program was originally constructed so safety-net health care facilities could stretch scarce resources in caring for low-income patients. However, the program has experienced ...

The 340B program, once a lifeline for underserved communities, has become a case study in crony capitalism. Designed to help hospitals serving low-income patients by offering discounted prescription ...

The 340B program, intended to lower drug costs for low-income patients, often benefits hospitals more than patients. A lack of transparency allows some hospitals to profit from the program instead of ...

The drugmaker has joined Johnson & Johnson and Eli Lilly in filing suit against the Biden administration over controversial reform to the drug discount program. The 340B program was created more than ...